AI Program May Aid in Pathologic Evaluation of Breast Biopsies
Computer - based automated approach promising for differentiating ductal carcinoma in situ from atypia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Surgery, Journal, Source Type: news
Study gives insight into breast cancer recurrence
(University of Manchester) Work by University of Manchester scientists has explored what allows some cases of Ductal Carcinoma in Situ, a non-invasive form of breast cancer, to resist treatment and come back, as well as identifying a potential new target to improve the effectiveness of radiotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 5, 2014 Category: Cancer & Oncology Source Type: news
Should ductal carcinoma in situ be treated
Read the full story on MD Consult:
Should ductal carcinoma in situ be treated (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - October 20, 2014 Category: Journals (General) Source Type: news
Tamoxifen Gel Equal to Oral Tx in DCIS
(MedPage Today) -- A topical formulation of tamoxifen matched oral therapy for antiproliferative activity in ductal carcinoma in situ with fewer potentially troublesome effects on endocrine and coagulation parameters, a small randomized trial showed. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - July 15, 2014 Category: Endocrinology Source Type: news
What Is Ductal Carcinoma In Situ?
A description and definition of ductal carcinoma in situ, with signs and symptoms, diagnostic tests, staging, and treatment. Learn more about early stage breast cancer here. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 4, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Telormedix completes Phase II trial of Vesimune for carcinoma in situ of the bladder
Switzerland-based biopharmaceutical firm Telormedix has completed an open-label Phase II clinical trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder. (Source: Drug Development Technology)
Source: Drug Development Technology - May 19, 2014 Category: Pharmaceuticals Source Type: news
First genetic link discovered to difficult-to-diagnose breast cancer sub-type
The discovery of the genetic variant, in conjunction with other markers, could help in the development of future genetic screening tools to assess women's risk of developing invasive lobular cancer, and also gives researchers important new clues about the genetic causes of the disease and a related precursor to cancer called lobular carcinoma in situ. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 17, 2014 Category: Science Source Type: news
First genetic link discovered to difficult-to-diagnose breast cancer sub-type
(Institute of Cancer Research) The discovery of the genetic variant, in conjunction with other markers, could help in the development of future genetic screening tools to assess women's risk of developing invasive lobular cancer, and also gives researchers important new clues about the genetic causes of the disease and a related precursor to cancer called lobular carcinoma in situ. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2014 Category: Cancer & Oncology Source Type: news
Novel Imaging Method Doubles Detection of DCISNovel Imaging Method Doubles Detection of DCIS
Even at doses lower than standard, digital mammography with a new photon-counting technique resulted in twice the rate of ductal carcinoma in situ being detected in a German study. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mastectomy not always best to treat breast cancer early, researchers say
In some cases women would have been better off having lumpectomy rather than having breast removed, study claimsUp to 200 British women diagnosed with an early form of breast cancer each year might be undergoing mastectomies because of failures in managing treatment, researchers have suggested.Failures by radiologists or pathologists to accurately measure the disease, lack of communication between specialist hospital teams and the patients' choice of surgical procedure mean women are not getting the optimum treatment.In some cases, women would have been better off having a lumpectomy – known as breast conservation surger...
Source: Guardian Unlimited Science - March 21, 2014 Category: Science Authors: James Meikle Tags: Breast cancer Health Society Medical research Science NHS UK news The Guardian Editorial Source Type: news
Audit of NHS Breast Screening Programme reveals significant variations between hospitals in adverse outcomes for treatment of ductal carcinoma in situ
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 21, 2014 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Significant variations between NHS hospitals in adverse outcomes for treatment of DCIS
(ECCO-the European CanCer Organisation) Analysis of data from the United Kingdom NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ between United Kingdom hospitals, according to research presented at the European Breast Cancer Conference. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2014 Category: Global & Universal Source Type: news
Early animal research into blocking breast cancer
"'An injection that prevents breast cancer is being developed by scientists," is the news on the Mail Online website.
This news seems a heartening way to start the year, but a caveat is that the research is in the very early stages – as yet only tested in mice.
The researchers were interested in a type of breast cancer known as ductal carcinoma in situ (DCIS).
In DCIS the cancerous cells are contained within the ducts in the breast, and not spread to other breast tissue. The problem with DCIS is that it is currently impossible to predict whether the cancer will remain inside the duct (so will not require tr...
Source: NHS News Feed - January 2, 2014 Category: Consumer Health News Tags: Cancer Source Type: news
Breast cancer jab 'prevents the disease in 75% of cases': Treatment could spare thousands of women the trauma of surgery
The main beneficiaries of the jab developed in the U.S. are likely to be women with a very early form of breast cancer called ductal carcinoma in situ, or DCIS. (Source: the Mail online | Health)
Source: the Mail online | Health - January 2, 2014 Category: Consumer Health News Source Type: news
